NF-&#x03BA;B/RelA-PKM2 mediates inhibition of glycolysis by fenofibrate in glioblastoma cells

Dongfeng Han; Wenjin Wei; Xincheng Chen; Yaxuan Zhang; Yingyi Wang; Junxia Zhang; Xiefeng Wang; Tianfu Yu; Qi Hu; Ning Liu; Yongping You

doi:10.18632/oncotarget.4444

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

NF-κB/RelA-PKM2 mediates inhibition of glycolysis by fenofibrate in glioblastoma cells

Dongfeng Han, Wenjin Wei, Xincheng Chen, Yaxuan Zhang, Yingyi Wang, Junxia Zhang, Xiefeng Wang, Tianfu Yu, Qi Hu, Ning Liu and Yongping You _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:26119-26128. https://doi.org/10.18632/oncotarget.4444

Metrics: PDF 4240 views | HTML 2937 views | ?

Abstract

Dongfeng Han1,*, Wenjin Wei1,*, Xincheng Chen1,*, Yaxuan Zhang1,*, Yingyi Wang1, Junxia Zhang1, Xiefeng Wang1, Tianfu Yu1, Qi Hu1, Ning Liu1, Yongping You1

1Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

*These authors have contributed equally to this work

Correspondence to:

Yongping You, e-mail: [email protected]

Keywords: fenofibrate, PPARα, RelA, PKM2, Warburg effect

Received: February 16, 2015 Accepted: June 19, 2015 Published: June 30, 2015

ABSTRACT

Aerobic glycolysis (production of lactate from glucose in the presence of oxygen) is a hallmark of cancer. Fenofibrate is a lipid-lowering drug and an agonist of the peroxisome proliferator-activated receptor alpha (PPARα). We found that FF inhibited glycolysis in a PPARα-dependent manner in glioblastoma cells. Fenofibrate inhibited the transcriptional activity of NF-κB/RelA and also disrupted its association with hypoxia inducible factor1 alpha (HIF1α), which is required for the binding of NF-κB/RelA to the PKM promoter and PKM2 expression. High ratios of PKM2/PKM1 promote glycolysis and inhibit oxidative phosphorylation, thus favoring aerobic glycolysis. Fenofibrate decreased the PKM2/PKM1 ratio and caused mitochondrial damage. Given that fenofibrate is a widely used non-toxic drug, we suggest its use in patients with glioblastoma multiforme (GBM).

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4444

Publication Alerts

Research Papers:

NF-κB/RelA-PKM2 mediates inhibition of glycolysis by fenofibrate in glioblastoma cells

Abstract